Sign In
Buy ADPT
$17.37
-0.160 (-0.91%)
At Close: Jun 22, 2026
Adaptive Biotechnologies Business Separation May Unlock Greater Value
01:21pm, Wednesday, 17'th Jun 2026
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
06:00am, Wednesday, 17'th Jun 2026
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
10:42am, Tuesday, 16'th Jun 2026
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medic
Adaptive Biotechnologies plans separation of immune medicine platform
04:47pm, Monday, 15'th Jun 2026
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focus
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
04:10pm, Monday, 15'th Jun 2026
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI MRD has scale
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
04:05pm, Monday, 15'th Jun 2026
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repu
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
06:26pm, Sunday, 14'th Jun 2026
Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share. The transactio
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
06:45am, Friday, 12'th Jun 2026
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
06:05pm, Wednesday, 03'rd Jun 2026
Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
04:03pm, Tuesday, 26'th May 2026
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:17pm, Thursday, 21'st May 2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:17pm, Thursday, 21'st May 2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
10:21pm, Tuesday, 05'th May 2026
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key
